Pozelimab
Veopoz (pozelimab) is an antibody pharmaceutical. Pozelimab was first approved as Veopoz on 2023-08-18. It is used to treat protein-losing enteropathies in the USA. It is known to target complement C5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Veopoz
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pozelimab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Veopoz | pozelimab-bbfg | Regeneron Pharmaceuticals | N-761339 RX | 2023-08-18 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| veopoz | Biologic Licensing Application | 2024-03-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| protein-losing enteropathies | HP_0002243 | D011504 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
pozelimab, Veopoz, Regeneron Pharmaceuticals, Inc. | |||
| 2030-08-18 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | 3 | 4 | — | 1 | 8 |
| Hemoglobinuria | D006456 | — | R82.3 | — | 3 | 4 | — | 1 | 8 |
| Protein-losing enteropathies | D011504 | HP_0002243 | — | — | 1 | 1 | — | 1 | 2 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | — | 1 | 1 | — | 1 | 2 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | — | 1 | — | — | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | — | — | 1 | — | — | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | 1 | — | — | 1 |
| Geographic atrophy | D057092 | — | — | — | — | 1 | — | — | 1 |
| Atrophy | D001284 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Myositis | D009220 | EFO_0000783 | G72.49 | 1 | — | — | — | — | 1 |
| Inclusion body myositis | D018979 | EFO_0007323 | G72.41 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pozelimab |
| INN | pozelimab |
| Description | Pozelimab, sold under the brand name Veopoz, is a recombinant monoclonal antibody used for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease. Pozelimab is a complement inhibitor. It is produced using recombinant DNA technology in Chinese hamster ovary cells.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2096328-94-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298086 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15218 |
| UNII ID | 0JJ21K6L2I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
C5
C5
Organism
Homo sapiens
Gene name
C5
Gene synonyms
CPAMD4
NCBI Gene ID
Protein name
complement C5
Protein synonyms
anaphylatoxin C5a analog, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, C5a anaphylatoxin, complement component 5, prepro-C5
Uniprot ID
Mouse ortholog
Hc (15139)
complement C5 (P06684)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 72 documents
View more details
Safety
Black-box Warning
Black-box warning for: Veopoz
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use